The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Differences in breast carcinoma characteristics in newly diagnosed African–American and Caucasian patients: A single‐institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and end results database
Abstract
BACKGROUND: Breast carcinomas in African–American patients appear to be more aggressive than in Caucasian patients due to multifactorial differences. METHODS: The authors compiled pathology data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database regarding stage, histologic grade, and estrogen receptor (ER) expression in breast carcinomas diagnosed in 197,274 African–American and Caucasian patients between 1990 and 2000, and the same information, along with nuclear grade, Ki‐67, c‐erb‐B2, and p53 expression, in 2230 African–American and Caucasian patients diagnosed at Thomas Jefferson University Hospital between 1995 and 2002. Immunohistochemical markers were assayed in paraffin‐embedded, formalin‐fixed tissue stained with hematoxylin and eosin using antibodies to these proteins, with differences in expression analyzed by the chisquare test. RESULTS: In both databases, more African–American patients presented with advanced stage tumors and higher histologic (P < .001) and nuclear grade (P < .001) than Caucasian patients. African–American patients had less ER positivity (51.9% vs 63.1%; P < .001) but significantly higher Ki‐67 (42.4% vs 28.7%; P < .001) and p53 expression (19.4% vs 13.1%; P < .05) than Caucasian patients with all stages of disease. In addition, the basal or “triple‐negative” breast cancer phenotype was more common in African–American patients than in Caucasian patients (20.8% vs 10.4%; P < .0001), and was associated with higher histologic and nuclear grade (P < .0001). CONCLUSIONS: African–American patients with breast carcinomas are more likely than Caucasian patients to present with tumors that are of a later stage and higher grade, with higher Ki‐67 expression and more ER negativity, thereby highlighting a greater need for early screening among African–American women. Molecular studies that may explain these differences, and correlations with survival, have been proposed to identify therapeutic targets. Cancer 2007. © 2007 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Tiwari, R. C., Murray, T., Ghafoor, A., Samuels, A., Ward, E., Feuer, E. J., & Thun, M. J. (2004) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.1.8 · Cited by 3,984
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
Carey, L. A., Perou, C. M., Livasy, C. A., Dressler, L. G., Cowan, D., Conway, K., Karaca, G., Troester, M. A., Tse, C. K., Edmiston, S., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2492 · Cited by 3,819
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-2-316_4 · Cited by 1,926
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N., Cristofanilli, M., Anderson, K., Hess, K. R., Stec, J., Ayers, M., Wagner, P., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2421 · Cited by 1,891
Lannin, D. R. (1998) · JAMA · doi:10.1001/jama.279.22.1801 · Cited by 666
Ethnicity and Breast Cancer: Factors Influencing Differences in Incidence and Outcome
Chlebowski, R. T., Chen, Z., Anderson, G. L., Rohan, T., Aragaki, A., Lane, D., Dolan, N. C., Paskett, E. D., McTiernan, A., Hubbell, F. A., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji064 · Cited by 656
Missed Opportunities: Racial Disparities in Adjuvant Breast Cancer Treatment
Bickell, N. A., Wang, J. J., Oluwole, S., Schrag, D., Godfrey, H., Hiotis, K., Mendez, J., & Guth, A. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5799 · Cited by 363
Newman, L. A., Griffith, K. A., Jatoi, I., Simon, M. S., Crowe, J. P., & Colditz, G. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.3472 · Cited by 362
Racial Disparities in Treatment and Survival Among Women With Early-Stage Breast Cancer
Hershman, D., McBride, R., Jacobson, J. S., Lamerato, L., Roberts, K., Grann, V. R., & Neugut, A. I. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.633 · Cited by 308
Cancer statistics by race and ethnicity
Parker, S. L., Davis, K. J., Wingo, P. A., Ries, L. A., & Heath, C. W. (1998) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.48.1.31 · Cited by 294
Cited by
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Triple-negative breast cancer molecular subtyping and treatment progress
Yin, L., Duan, J.-J., Bian, X.-W., & Yu, S.-C. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01296-5 · Cited by 2,452
Burstein, M. D., Tsimelzon, A., Poage, G. M., Covington, K. R., Contreras, A., Fuqua, S. A. W., Savage, M. I., Osborne, C. K., Hilsenbeck, S. G., Chang, J. C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0432 · Cited by 1,392
Triple-negative breast cancer in African-American women: disparities versus biology
Dietze, E. C., Sistrunk, C., Miranda-Carboni, G., O'Regan, R., & Seewaldt, V. L. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3896 · Cited by 898
Triple negative tumours: a critical review
Reis‐Filho, J. S., & Tutt, A. N. J. (2008) · Histopathology · doi:10.1111/j.1365-2559.2007.02889.x · Cited by 884
Triple-negative breast cancer: disease entity or title of convenience?
Carey, L., Winer, E., Viale, G., Cameron, D., & Gianni, L. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.154 · Cited by 783
Breast Cancer: Epidemiology and Etiology
Tao, Z., Shi, A., Lu, C., Song, T., Zhang, Z., & Zhao, J. (2015) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-014-0459-6 · Cited by 699
Triple-negative breast cancer—current status and future directions
Gluz, O., Liedtke, C., Gottschalk, N., Pusztai, L., Nitz, U., & Harbeck, N. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp492 · Cited by 687
Badve, S., Dabbs, D. J., Schnitt, S. J., Baehner, F. L., Decker, T., Eusebi, V., Fox, S. B., Ichihara, S., Jacquemier, J., Lakhani, S. R., et al. (2011) · Modern Pathology · doi:10.1038/modpathol.2010.200 · Cited by 680
Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast Cancer
Anders, C. K., & Carey, L. A. (2009) · Clinical Breast Cancer · doi:10.3816/cbc.2009.s.008 · Cited by 625
Dissecting the Heterogeneity of Triple-Negative Breast Cancer
Metzger-Filho, O., Tutt, A., de Azambuja, E., Saini, K. S., Viale, G., Loi, S., Bradbury, I., Bliss, J. M., Azim, H. A., Ellis, P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.2010 · Cited by 465
Albain, K. S., Unger, J. M., Crowley, J. J., Coltman, C. A., & Hershman, D. L. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp175 · Cited by 458
Triple-Negative Breast Cancer: Risk Factors to Potential Targets
Schneider, B. P., Winer, E. P., Foulkes, W. D., Garber, J., Perou, C. M., Richardson, A., Sledge, G. W., & Carey, L. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1208 · Cited by 437
Basal Breast Cancer: A Complex and Deadly Molecular Subtype
Bertucci, F., Finetti, P., & Birnbaum, D. (2012) · Current Molecular Medicine · doi:10.2174/156652412798376134 · Cited by 394
Triple-negative breast cancer: is there a treatment on the horizon?
Yao, H., He, G., Yan, S., Chen, C., Song, L., Rosol, T. J., & Deng, X. (2017) · Oncotarget · doi:10.18632/oncotarget.12284 · Cited by 394
Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA
Lund, M. J., Trivers, K. F., Porter, P. L., Coates, R. J., Leyland-Jones, B., Brawley, O. W., Flagg, E. W., O’Regan, R. M., Gabram, S. G. A., & Eley, J. W. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-9926-3 · Cited by 390
The fate of chemoresistance in triple negative breast cancer (TNBC)
O’Reilly, E. A., Gubbins, L., Sharma, S., Tully, R., Guang, M. H. Z., Weiner-Gorzel, K., McCaffrey, J., Harrison, M., Furlong, F., Kell, M., et al. (2015) · BBA Clinical · doi:10.1016/j.bbacli.2015.03.003 · Cited by 377
Hall, M. J., Reid, J. E., Burbidge, L. A., Pruss, D., Deffenbaugh, A. M., Frye, C., Wenstrup, R. J., Ward, B. E., Scholl, T. A., & Noll, W. W. (2009) · Cancer · doi:10.1002/cncr.24200 · Cited by 365
Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies
Lee, A., & Djamgoz, M. B. A. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.003 · Cited by 354
What is triple-negative breast cancer?
Irvin, W. J., & Carey, L. A. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.09.034 · Cited by 350
The epidemiology of triple-negative breast cancer, including race
Trivers, K. F., Lund, M. J., Porter, P. L., Liff, J. M., Flagg, E. W., Coates, R. J., & Eley, J. W. (2009) · Cancer Causes & Control · doi:10.1007/s10552-009-9331-1 · Cited by 332
Recent advances in targeted strategies for triple-negative breast cancer
Zhu, S., Wu, Y., Song, B., Yi, M., Yan, Y., Mei, Q., & Wu, K. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01497-3 · Cited by 331
Triple negative breast cancer: unmet medical needs
Pal, S. K., Childs, B. H., & Pegram, M. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1293-1 · Cited by 322
Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors
Kwan, M. L., Kushi, L. H., Weltzien, E., Maring, B., Kutner, S. E., Fulton, R. S., Lee, M. M., Ambrosone, C. B., & Caan, B. J. (2009) · Breast Cancer Research · doi:10.1186/bcr2261 · Cited by 318
Tan, D. S. P., Marchió, C., Jones, R. L., Savage, K., Smith, I. E., Dowsett, M., & Reis-Filho, J. S. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9756-8 · Cited by 318
Characteristics of triple-negative breast cancer
de Ruijter, T. C., Veeck, J., de Hoon, J. P. J., van Engeland, M., & Tjan-Heijnen, V. C. (2011) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0957-x · Cited by 317
Triple‐negative breast cancer: Present challenges and new perspectives
Podo, F., Buydens, L. M. C., Degani, H., Hilhorst, R., Klipp, E., Gribbestad, I. S., Van Huffel, S., W.M. van Laarhoven, H., Luts, J., Monleon, D., et al. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.04.006 · Cited by 299
TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer
Chen, X., Li, J., Gray, W. H., Lehmann, B. D., Bauer, J. A., Shyr, Y., & Pietenpol, J. A. (2012) · Cancer Informatics · doi:10.4137/cin.s9983 · Cited by 292
Risk Factors for Triple-Negative Breast Cancer in Women Under the Age of 45 Years
Dolle, J. M., Daling, J. R., White, E., Brinton, L. A., Doody, D. R., Porter, P. L., & Malone, K. E. (2009) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-1005 · Cited by 271
Triple negative breast cancers: Clinical and prognostic implications
Dawson, S. J., Provenzano, E., & Caldas, C. (2009) · European Journal of Cancer · doi:10.1016/s0959-8049(09)70013-9 · Cited by 266
Thike, A. A., Cheok, P. Y., Jara-Lazaro, A. R., Tan, B., Tan, P., & Tan, P. H. (2010) · Modern Pathology · doi:10.1038/modpathol.2009.145 · Cited by 257
Triple-Negative Breast Cancer: Epidemiology and Management Options
Dawood, S. (2010) · Drugs · doi:10.2165/11538150-000000000-00000 · Cited by 253
Scott, L. C., Mobley, L. R., Kuo, T., & Il’yasova, D. (2019) · Cancer · doi:10.1002/cncr.32207 · Cited by 165
Ma, Y., Wang, J., Li, Q., & Cao, B. (2021) · Nutrition and Cancer · doi:10.1080/01635581.2020.1743873 · Cited by 27
Metadata
- Authors
- Morris, G. J., Naidu, S., Topham, A. K., Guiles, F., Xu, Y., McCue, P., Schwartz, G. F., Park, P. K., Rosenberg, A. L., Brill, K., & Mitchell, E. P.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2007-07-09
- Volume
- 110
- Issue
- 4
- Pages
- 876-884
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1839791863
- Cited by
- 602
- References
- 29
- FWCI
- 9.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.